Kyron.bio is revolutionising the way we make our therapeutic drugs.

Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic  in order to develop the next generation of medicines.  This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. 

Our work at  Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical industry. 



Pharmaceutical

Life Sciences

Biotechnology

kyron.bio

kyron.bio's headquarters in Paris, France

Description

People (1)

Emilia McLaughlin

Jobs